Enanta PharmaceuticalsENTA
About: Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
Employees: 131
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
13% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 31
0% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]
8% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 26
3% less funds holding
Funds holding: 110 [Q3] → 107 (-3) [Q4]
7.2% less ownership
Funds ownership: 101.15% [Q3] → 93.95% (-7.2%) [Q4]
21% less call options, than puts
Call options by funds: $56K | Put options by funds: $71K
48% less capital invested
Capital invested by funds: $222M [Q3] → $114M (-$108M) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
JMP Securities Roy Buchanan 32% 1-year accuracy 8 / 25 met price target | 239%upside $21 | Market Outperform Reiterated | 11 Feb 2025 |
HC Wainwright & Co. Ed Arce 47% 1-year accuracy 72 / 154 met price target | 190%upside $18 | Buy Reiterated | 11 Feb 2025 |
Financial journalist opinion









